Fecal, duodenal, and tumor microbiota composition of esophageal carcinoma patients, a longitudinal prospective cohort
JNCI: Journal of the National Cancer Institute · 01.11.2024 · 116 (11) · 1834-1844
DOI: 10.1093/jnci/djae153 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 26.06.2024. Verfasst von Tom van den Ende und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Feces, Gastrointestinal Microbiome. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hoffmann-La Roche Ltd, AstraZeneca.
Abstract (Originalsprache)
Background
The microbiome has been associated with chemotherapy and immune checkpoint inhibitor efficacy. How this pertains to resectable esophageal carcinoma is unknown. Our aim was to identify microbial signatures in resectable esophageal carcinoma associated with response to neoadjuvant chemoradiotherapy with or without an immune checkpoint inhibitor.
Methods
From 2 prospectively collected esophageal carcinoma cohorts (n = 172 in total) treated with neoadjuvant chemoradiotherapy alone (n = 132) or a combination of neoadjuvant chemoradiotherapy and an immune checkpoint inhibitor (n = 40), fecal samples were available at baseline, during treatment, and presurgery. Additionally, in the immune checkpoint inhibitor–treated patients, tumor and duodenal snap frozen biopsies were collected over time. Fecal, tumor, and duodenal DNA were extracted for 16S ribosomal RNA sequencing. Associations were investigated between microbiome composition pathological complete response and progression-free survival (PFS).
Results
There was a statistically significant shift in the microbiota profile of the fecal, tumor, and duodenal microbiota over time. In the total cohort, patients with a pathological complete response had a stable fecal alpha diversity, while the diversity of poor responders decreased during treatment (P = .036). Presurgery, lower alpha diversity (<4.12) was related to worse PFS (log-rank P = .025). Baseline tumor biopsies of patients with short PFS had more Fusobacterium. A low baseline duodenal alpha diversity (<3.96) was associated with worse PFS (log-rank P = .012).
Conclusions
Lower intestinal alpha diversity was associated with worse response and survival of esophageal carcinoma patients. In tumor biopsies, Fusobacterium was more abundant in patients with poor PFS. After further mechanistic validation, these findings may aid in response prediction and the design of novel microbiome modulating treatments for esophageal carcinoma patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands.
- Department of Internal and Vascular Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
- Netherlands Cancer Institute, Gastrointestinal Oncology, Amsterdam, the Netherlands.
- Oncode Institute, Utrecht, the Netherlands.
- Center for Experimental and Molecular Medicine, Amsterdam University Medical Center, University of Amsterdam, Laboratory for Experimental Oncology and Radiobiology, Amsterdam, the Netherlands.
ORCID-Profile: Tom van den Ende, Max Nieuwdorp
Förderung
- Hoffmann-La Roche Ltd
- AstraZeneca
Zitieren
APA
van den Ende, T., de Clercq, N. C., Davids, M., Goedegebuure, R., Doeve, B. H., Ebrahimi, G., Buijsen, J., Hoekstra, R., Mohammad, N. H., Bijlsma, M. F., Nieuwdorp, M., & van Laarhoven, H. W. M. (2024). Fecal, duodenal, and tumor microbiota composition of esophageal carcinoma patients, a longitudinal prospective cohort. JNCI: Journal of the National Cancer Institute, 116(11), 1834-1844. https://doi.org/10.1093/jnci/djae153
Vancouver
van den Ende T, de Clercq NC, Davids M, Goedegebuure R, Doeve BH, Ebrahimi G, et al. Fecal, duodenal, and tumor microbiota composition of esophageal carcinoma patients, a longitudinal prospective cohort. JNCI: Journal of the National Cancer Institute. 2024;116(11):1834-1844. doi:10.1093/jnci/djae153
BibTeX
@article{vandenEnde2024,
author = {van den Ende, Tom and de Clercq, Nicolien C and Davids, Mark and Goedegebuure, Ruben and Doeve, Benthe H and Ebrahimi, Gati and Buijsen, Jeroen and Hoekstra, Ronald and Mohammad, Nadia Haj and Bijlsma, Maarten F and Nieuwdorp, Max and van Laarhoven, Hanneke W M},
title = {Fecal, duodenal, and tumor microbiota composition of esophageal carcinoma patients, a longitudinal prospective cohort},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2024},
volume = {116},
number = {11},
pages = {1834--1844},
doi = {10.1093/jnci/djae153}
}
EUVIMED